Skip to content

Long Term Results in Hypoplastic Aortic Arch Repair in Neonates Using a Glutaraldehyde Treated Autologous Pericardial Patch

Retrospective Analysis of Results in Children Treated by an Autologous Pericardial Patch to Repair a Hypoplastic Aortic Arch Associated to Other Congenital Heart Defects

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03588312
Acronym
Aortoplasty
Enrollment
80
Registered
2018-07-17
Start date
2018-01-01
Completion date
2018-09-01
Last updated
2018-07-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Congenital Hypoplasia of Aortic Arch

Keywords

Aortic arch hypoplasia, Glutaraldehyde treated autologous pericardium, Single stage repair, Congenital heart defects, Newborns

Brief summary

Hypoplastic aortic arch is a congenital heart defect that is prejudicial for the growth of newborns. It is often associated to other heart defects. Different surgical techniques exist to address this defect, but the literature is very poor with regards to the use of an autologous pericardial patch. Most use extensive dissection techniques or synthetic patches. Here investigators report institution's original approach using the newborns own pericardium for what investigators believe to be an optimal correction of the hypoplasia., with preserved growth potential.

Detailed description

Retrospective analysis of an already well codified surgical intervention carried out in HUDERF under extra-corporeal circulation

Interventions

PROCEDUREAortoplasty using autologous pericardial patch

hypoplastic aortic arch repair using a glutaraldehyde treated, autologous pericardial patch.

Sponsors

Queen Fabiola Children's University Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
No minimum to 2 Years
Healthy volunteers
No

Inclusion criteria

* Newborns with a hypoplastic aortic arch undergoing a first intervention

Exclusion criteria

* none

Design outcomes

Primary

MeasureTime frame
Overall survival30 days post surgery

Secondary

MeasureTime frame
Freedom from re-interventionUp to 18 years post initial surgery

Countries

Belgium

Contacts

Primary ContactLouis Chebli, MD
louis.chebli@chu-brugmann.be0032 475262210
Backup ContactPierre Wauthy, MD PhD
pierre.wauthy@chu-brugmann.be0032 2 4772111

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026